Patents Assigned to Institut Catala D'oncologia
  • Oncolytic adenoviruses for treating cancer
    Patent number: 12129280
    Abstract: The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: October 29, 2024
    Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMEDICA DE BELLVITGE, INSTITUT CATALA D'ONCOLOGIA
    Inventors: Sònia Guedan Carrió, Manel Maria Cascallo Piqueras, Ramon Alemany Bonastre
  • PD-ECGF as biomarker of cancer
    Patent number: 11802874
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 31, 2023
    Assignees: FUNDACIO INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Oriol Casanovas Casanovas, Gabriela Jiménez Valerio, María Ochoa De Olza, Valentí Navarro Pérez, Nicklas Bassani, Helena Verdaguer
  • Adenovirus comprising an albumin-binding moiety
    Patent number: 11578104
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: February 14, 2023
    Assignees: Fundació Institut D'lnvestigació Biomedica De Bellvitge (í DIBELL), INSTITUT CATALA D'ONCOLOGIA (ICO)
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • Adenovirus comprising an albumin-binding moiety
    Patent number: 10604549
    Abstract: The invention relates to a recombinant adenovirus comprising an albumin-binding moiety on the outer surface of the adenoviral hexon protein, pharmaceutical compositions containing it and its medical use. Particularly, the invention relates to an oncolytic adenovirus comprising a sequence encoding an albumin-binding moiety inserted in the hypervariable region 1 (HVR1) of the hexon protein coding sequence and its use in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: March 31, 2020
    Assignees: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Ramon Alemany Bonastre, Luis Alfonso Rojas Expósito
  • Oncolytic adenoviruses for treating cancer
    Patent number: 10316065
    Abstract: The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously results in tumour volume regressions. Therefore, the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: June 11, 2019
    Assignees: Fundacio Institut d Investigacio Biomedica de Bellvitge (IDIBELL), Institut Catala D Oncologia
    Inventors: Sònia Guedan Carrió, Manel Maria Cascallo Piqueras, Ramon Alemany Bonastre
  • PD-ECGF AS BIOMARKER OF CANCER
    Publication number: 20180052164
    Abstract: The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
    Type: Application
    Filed: March 10, 2016
    Publication date: February 22, 2018
    Applicants: FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUT CATALÀ D'ONCOLOGIA (ICO)
    Inventors: Oriol CASANOVAS CASANOVAS, Gabriela JIMÉNEZ VALERIO, María OCHOA DE OLZA, Valentí NAVARRO PÉREZ, Nicklas BASSANI, Helena VERDAGUER
  • Adenovirus With Mutations in the Endoplasmic Reticulum Retention Domain of the E3-19K Protein and Their Use in Cancer Treatment
    Publication number: 20100124546
    Abstract: The present invention relates to an adenovirus wherein said adenovirus replicates and it contains a mutation in the endoplasmic reticulum retention domain of E3-19K, and to the use of said mutant in treating cancer. Said mutant virus may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy.
    Type: Application
    Filed: September 10, 2009
    Publication date: May 20, 2010
    Applicant: Institut Catala D'oncologia
    Inventors: Manel Maria Cascallo Piqueras, Alena Gros, Ramon Alemany Bonastre